Arcellx Future Growth
Future criteria checks 2/6
Arcellx is forecast to grow earnings and revenue by 22.5% and 30.9% per annum respectively. EPS is expected to grow by 21.1% per annum. Return on equity is forecast to be -8.6% in 3 years.
Key information
22.5%
Earnings growth rate
21.1%
EPS growth rate
Biotechs earnings growth | 27.2% |
Revenue growth rate | 30.9% |
Future return on equity | -8.6% |
Analyst coverage | Good |
Last updated | 26 Jan 2025 |
Recent future growth updates
Recent updates
Arcellx, Inc.: Trying To Build A Better Myeloma Cell Therapy
Jan 16Risks To Shareholder Returns Are Elevated At These Prices For Arcellx, Inc. (NASDAQ:ACLX)
Dec 20A Look At The Fair Value Of Arcellx, Inc. (NASDAQ:ACLX)
Oct 28Arcellx's Anito-Cel: Compelling Opportunity As Potential Best-In-Class CAR-T Therapy For Multiple Myeloma
Sep 10There's Reason For Concern Over Arcellx, Inc.'s (NASDAQ:ACLX) Massive 28% Price Jump
Sep 05We're Interested To See How Arcellx (NASDAQ:ACLX) Uses Its Cash Hoard To Grow
Aug 10A Look At The Fair Value Of Arcellx, Inc. (NASDAQ:ACLX)
Jul 12News Flash: Analysts Just Made A Sizeable Upgrade To Their Arcellx, Inc. (NASDAQ:ACLX) Forecasts
Jun 01Rainbows and Unicorns: Arcellx, Inc. (NASDAQ:ACLX) Analysts Just Became A Lot More Optimistic
May 14Is Arcellx (NASDAQ:ACLX) A Risky Investment?
May 12Arcellx, Inc. (NASDAQ:ACLX) Just Reported And Analysts Have Been Lifting Their Price Targets
Mar 01Arcellx: Navigating The CAR T-Cell Revolution
Jan 30Need To Know: Analysts Are Much More Bullish On Arcellx, Inc. (NASDAQ:ACLX) Revenues
Nov 18Earnings Miss: Arcellx, Inc. Missed EPS And Analysts Are Revising Their Forecasts
May 10Companies Like Arcellx (NASDAQ:ACLX) Are In A Position To Invest In Growth
Nov 17Arcellx: The Best Is Yet To Come
Aug 23Arcellx GAAP EPS of -$0.88
Aug 15Arcellx down 9% on day lock-up period ends
Aug 03We're Hopeful That Arcellx (NASDAQ:ACLX) Will Use Its Cash Wisely
Jun 27Arcellx: Speculative Buy For Their 'Best-In-Class' CAR-T Cell Therapy
Jun 08Earnings and Revenue Growth Forecasts
Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
---|---|---|---|---|---|
12/31/2027 | 230 | -158 | -68 | -79 | 8 |
12/31/2026 | 184 | -139 | -99 | -66 | 12 |
12/31/2025 | 119 | -135 | -99 | -106 | 17 |
12/31/2024 | 122 | -87 | -76 | -68 | 17 |
9/30/2024 | 156 | -40 | 4 | 21 | N/A |
6/30/2024 | 145 | -54 | -43 | -20 | N/A |
3/31/2024 | 132 | -51 | -33 | -6 | N/A |
12/31/2023 | 110 | -71 | 186 | 208 | N/A |
9/30/2023 | 47 | -130 | 104 | 122 | N/A |
6/30/2023 | 32 | -183 | 105 | 115 | N/A |
3/31/2023 | 18 | -190 | 113 | 115 | N/A |
12/31/2022 | N/A | -189 | -102 | -99 | N/A |
9/30/2022 | N/A | -170 | -99 | -93 | N/A |
6/30/2022 | N/A | -95 | -94 | -89 | N/A |
3/31/2022 | N/A | -80 | -83 | -77 | N/A |
12/31/2021 | N/A | -65 | -60 | -54 | N/A |
9/30/2021 | N/A | -53 | -42 | -40 | N/A |
12/31/2020 | N/A | -32 | -30 | -29 | N/A |
12/31/2019 | N/A | -18 | -23 | -19 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: ACLX is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: ACLX is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: ACLX is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: ACLX's revenue (30.9% per year) is forecast to grow faster than the US market (8.9% per year).
High Growth Revenue: ACLX's revenue (30.9% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: ACLX is forecast to be unprofitable in 3 years.
Discover growth companies
Company Analysis and Financial Data Status
Data | Last Updated (UTC time) |
---|---|
Company Analysis | 2025/01/31 23:02 |
End of Day Share Price | 2025/01/31 00:00 |
Earnings | 2024/09/30 |
Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
Package | Data | Timeframe | Example US Source * |
---|---|---|---|
Company Financials | 10 years |
| |
Analyst Consensus Estimates | +3 years |
|
|
Market Prices | 30 years |
| |
Ownership | 10 years |
| |
Management | 10 years |
| |
Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Arcellx, Inc. is covered by 22 analysts. 17 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
Analyst | Institution |
---|---|
Jack Allen | Baird |
Peter Lawson | Barclays |
Carter Gould | Barclays |